Shukra Pharmaceuticals Ltd Share Price – BSE

Pharmaceuticals, Small Cap

Net profit of Shukra Pharmaceuticals rose 544.30% to Rs 20.36 crore in the quarter ended December 2025 as against Rs 3.16 crore during the previous quarter ended December 2024. Sales rose 269.85% to Rs 39.13 crore in the quarter ended December 2025 as against Rs 10.58 crore during the previous quarter ended December 2024.

Powered by Capital Market - Live News

Shukra Pharmaceuticals has revised the meeting of the Board of Directors which was scheduled to be held on 7 February 2026. The meeting will now be held on 4 February 2026.

Powered by Capital Market - Live News

Shukra Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 7 February 2026.

Powered by Capital Market - Live News

The MOU sets out the framework for collaboration between the parties to introduce, promote and commercialize next-generation Al-enabled soft-tissue surgical robotic systems across lndia and select South Asian markets, including Nepal, Bangladesh, Sri Lanka, Maldives and Bhutan, subject to applicable regulatory approvals.

Shukra Pharmaceuticals stated that this collaboration will focus on expanding access to robot-assisted minimally invasive surgeries, integrating AI-driven digital surgery workflows to improve standardization and efficiency, and strengthening regional healthcare infrastructure through technology transfer and clinician training.

Borns Medical Robotics will contribute its surgical robotics and AI expertise, while the company will leverage its regulatory capabilities and healthcare market reach across India and South Asia.

The collaboration supports the company?s long-term strategy of expanding into high-value, technology-led healthcare segments.

It is expected to strengthen its medical technology portfolio and market positioning, unlock new revenue opportunities through commercialization and hospital partnerships, enhance brand visibility and competitiveness in digital healthcare, and contribute to sustainable long-term shareholder value by gaining exposure to the fast-growing global surgical robotics market.

The MOU is non-binding in nature and outlines the intent of the parties to explore definitive agreements in due course, subject to detailed commercial terms, regulatory approvals, and mutual consent,? the company said in a statement.

Shukra Pharmaceuticals manufactures and markets pharmaceutical products and does laboratory testing.

The company's consolidated net profit surged to Rs 2.38 crore in the quarter ended September 2025 as against Rs 0.54 crore during the previous quarter ended September 2024. Sales rose 5.76% to Rs 5.88 crore in Q2 FY26 over Q2 FY25.

The scrip had declined 4.98% to end at Rs 54.15 on the BSE today.

Powered by Capital Market - Live News